Amitriptyline
Post Herpetic Neuralgia
Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Post Herpetic Neuralgia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eslicarbazepine Acetate Bial - Portela C S.A. | Phase 3 | BB |
Epicept-Np-1 Cream EpiCept Corporation | Phase 2 | B |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- EpiCept Corporation | Phase 2 | B |
Nxn-462 NeurAxon Inc. | Phase 2 | B |
ELCUBRAGISTAT Abide Therapeutics | Phase 1 | CC |
in1011-n17 iN Therapeutics Co., Ltd. | Phase 1 | CC |
in1011-n17 hcl iN Therapeutics Co., Ltd. | Phase 1 | CC |
Ajh-2947 JMackem Co., Ltd | Phase 1 | CC |
Same molecule, other indications
Amitriptyline is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →